HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Vernon Bernardino reiterates a Buy rating on Edesa Biotech (NASDAQ:EDSA) and maintains a $16 price target.
May 24, 2023 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edesa Biotech receives a reiterated Buy rating from HC Wainwright & Co. analyst Vernon Bernardino, with a maintained $16 price target.
The reiterated Buy rating and maintained $16 price target by HC Wainwright & Co. analyst Vernon Bernardino indicates a positive outlook for Edesa Biotech's stock in the short term. This news is highly relevant and important for investors, as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100